Cytosorbents (CTSO) Gross Profit (2011 - 2026)

Cytosorbents' Gross Profit history runs 16 years deep, the most recent figure standing at $6.1 million for Q1 2026.

• Quarterly Gross Profit fell 1.24% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.4 million (up 9.05% YoY) and the FY2025 annual result came in at $26.5 million, up 6.45% from the prior year.
• Gross Profit was $6.1 million for Q1 2026 at Cytosorbents, down from $6.8 million in the prior quarter.
• Across five years, Gross Profit topped out at $6.9 million in Q1 2024 and bottomed at $3.6 million in Q3 2022.
• A 5-year average of $5.9 million and a median of $6.1 million in 2026 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2022 — Gross Profit sank 50.43% — and 2023, when it surged 55.0%.
• Cytosorbents' Gross Profit stood at $5.8 million in 2022, then slipped by 7.74% to $5.3 million in 2023, then rose by 17.77% to $6.3 million in 2024, then grew by 8.78% to $6.8 million in 2025, then slipped by 9.91% to $6.1 million in 2026.
• Business Quant data shows CTSO's Gross Profit at $6.1 million in Q1 2026, $6.8 million in Q4 2025, and $6.7 million in Q3 2025.